姓名：徐建 性别：男 职称：副研究员、副教授 招生院所：胸科医院 招生类型：科学学位(硕) 招生专业：药理学(硕) 研究方向名称：抗结核药物药理学研究 电子信箱：xujian198303@hotmail.com


社会任职
1. 中国药理学会化疗药理专业委员会青年委员
2. 中国研究型医院学会空间微生物与感染专业委员会青年委员
个人简历
1. 200109-200507:山东大学 学士
2. 200509-200807:北京协和医学院 硕士
3. 201209-201507:北京协和医学院 博士
4. 201510-:北京市结核病胸部肿瘤研究所 副研究员 硕士生导师
5. 201609-201808:Johns Hopkins University 博士后
6. 201905-:首都医科大学附属北京胸科医院 副教授 硕士生导师
7. 201912-202012:青海省第四人民医院 挂职副院长（中组部博士服务团）
重要学术论文
1. Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrobial Agents and Chemotherapy. 2019,63(5):doi: 10.1128/AAC.00021-19.SCI
2. Xu J#, Wang B#, Fu L, Zhu H, Guo S, Huang H, Zhang Y, Lu Y.In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2019,63(5):doi: 10.1128/AAC.02155-18.SCI
3. Ren J#, Xu J#, Zhang G, Xu C, Zhao L, You X, Wang Y, Lu Y, Yu L.Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents. Bioorganic & Medicinal Chemistry Letters. 2019,29(4):539-543.SCI
4. Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL..Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay. Antimicrob Agents Chemother. 2019,63(7):doi: 10.1128/AAC.00426-19.SCI
5. Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E*.Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2018,62(1):doi: 10.1128/AAC.01692-17.SCI
6. Xu J, Wang JX,Zhou JM,Xu CL,Huang B,Xing Y,Wang B,Luo R,Wang YC,You XF,Lu Y,Yu LY.A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity. Scientific Reports. 2017,7(1):doi: 10.1038/s41598-017-04108-7.SCI
7. Xu J,Wang B,Hu M,Huo F,Guo S,Jing W,Nuermberger E,Lu Y.Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 2017,61(6):doi: 10.1128/AAC.00239-17.SCI
8. Xu C, Bai X, Xu J, Ren J, Xing Y, Li Z, Wang J, Shi J, Yu L, Wang Y.Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study. RSC Advances. 2017,7(8):4763-4775.SCI
9. Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG.In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015,59(1):136-144.SCI
10. Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. Clin Ther. 2013,35(2):161-168.SCI
11. Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P.In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis. 2012,16(8):1119-1125.SCI
主编或副主编的著作/译著
重要奖项